JAMA· 2015Q1

Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer

Agnes Lee, Pieter W. Kamphuisen, Guy Meyer, Rupert Bauersachs et al.

614citations
Q1SCImago
2015year

Short summary

In patients with active cancer and acute venous thromboembolism (VTE), full-dose tinzaparin for 6 months did not significantly reduce recurrent VTE compared to warfarin, but did show a lower rate of clinically relevant nonmajor bleeding.

AI-generated from the title and abstract; the full text is not read.

TakeawaysIn the app

Key pointsIn the app

Ask the paperIn the app

The rest is in the Pofolia app

Takeaways, key points and questions to the paper; new summaries every day for your field. Free.

Get it on Google Play Download on the App Store

Field: Internal Medicine

Internal MedicineMedicine